Acute lymphoblastic leukemia

The TCN2 rs1801198 polymorphism, which was more prevalent in Hispanic patients, was associated with inferior event-free survival within the Hispanic patient cohort in multivariable modeling, and was a

Effect: decline; HR=3.15

The TCN2 rs1801198 polymorphism, which was more prevalent in Hispanic patients, was associated with inferior event-free survival within the Hispanic patient cohort in multivariable modeling, and was a

Effect: decline; HR=3.15

The TCN2 rs1801198 polymorphism, which was more prevalent in Hispanic patients, was associated with inferior event-free survival within the Hispanic patient cohort in multivariable modeling, and was a

Effect: decline; HR=3.15

The TCN2 rs1801198 polymorphism, which was more prevalent in Hispanic patients, was associated with inferior event-free survival within the Hispanic patient cohort in multivariable modeling, and was a

Effect: decline; HR=3.15

The TCN2 rs1801198 polymorphism, which was more prevalent in Hispanic patients, was associated with inferior event-free survival within the Hispanic patient cohort in multivariable modeling, and was a

Effect: decline; HR=3.15

The TCN2 rs1801198 polymorphism, which was more prevalent in Hispanic patients, was associated with inferior event-free survival within the Hispanic patient cohort in multivariable modeling, and was a

Effect: decline; HR=3.15

The TCN2 rs1801198 polymorphism, which was more prevalent in Hispanic patients, was associated with inferior event-free survival within the Hispanic patient cohort in multivariable modeling, and was a

Effect: decline; HR=3.15

The TCN2 rs1801198 polymorphism, which was more prevalent in Hispanic patients, was associated with inferior event-free survival within the Hispanic patient cohort in multivariable modeling, and was a

Effect: decline; HR=3.15

The TCN2 rs1801198 polymorphism, which was more prevalent in Hispanic patients, was associated with inferior event-free survival within the Hispanic patient cohort in multivariable modeling, and was a

Effect: decline; HR=3.15

The TCN2 rs1801198 polymorphism, which was more prevalent in Hispanic patients, was associated with inferior event-free survival within the Hispanic patient cohort in multivariable modeling, and was a

Effect: decline; HR=3.15

The TCN2 rs1801198 polymorphism, which was more prevalent in Hispanic patients, was associated with inferior event-free survival within the Hispanic patient cohort in multivariable modeling, and was a

Effect: decline; HR=3.15

The TCN2 rs1801198 polymorphism, which was more prevalent in Hispanic patients, was associated with inferior event-free survival within the Hispanic patient cohort in multivariable modeling, and was a

Effect: decline; HR=3.15

The TCN2 rs1801198 polymorphism, which was more prevalent in Hispanic patients, was associated with inferior event-free survival within the Hispanic patient cohort in multivariable modeling, and was a

Effect: decline; HR=3.15

The TCN2 rs1801198 polymorphism, which was more prevalent in Hispanic patients, was associated with inferior event-free survival within the Hispanic patient cohort in multivariable modeling, and was a

Effect: decline; HR=3.15

The TCN2 rs1801198 polymorphism, which was more prevalent in Hispanic patients, was associated with inferior event-free survival within the Hispanic patient cohort in multivariable modeling, and was a

Effect: decline; HR=3.15

The TCN2 rs1801198 polymorphism, which was more prevalent in Hispanic patients, was associated with inferior event-free survival within the Hispanic patient cohort in multivariable modeling, and was a

Effect: decline; HR=3.15

The TCN2 rs1801198 polymorphism, which was more prevalent in Hispanic patients, was associated with inferior event-free survival within the Hispanic patient cohort in multivariable modeling, and was a

Effect: decline; HR=3.15

The TCN2 rs1801198 polymorphism, which was more prevalent in Hispanic patients, was associated with inferior event-free survival within the Hispanic patient cohort in multivariable modeling, and was a

Effect: decline; HR=3.15

The TCN2 rs1801198 polymorphism, which was more prevalent in Hispanic patients, was associated with inferior event-free survival within the Hispanic patient cohort in multivariable modeling, and was a

Effect: decline; HR=3.15

The TCN2 rs1801198 polymorphism, which was more prevalent in Hispanic patients, was associated with inferior event-free survival within the Hispanic patient cohort in multivariable modeling, and was a

Effect: decline; HR=3.15

The TCN2 rs1801198 polymorphism, which was more prevalent in Hispanic patients, was associated with inferior event-free survival within the Hispanic patient cohort in multivariable modeling, and was a

Effect: decline; HR=3.15

The TCN2 rs1801198 polymorphism, which was more prevalent in Hispanic patients, was associated with inferior event-free survival within the Hispanic patient cohort in multivariable modeling, and was a

Effect: decline; HR=3.15

The TCN2 rs1801198 polymorphism, which was more prevalent in Hispanic patients, was associated with inferior event-free survival within the Hispanic patient cohort in multivariable modeling, and was a

Effect: decline; HR=3.15

The TCN2 rs1801198 polymorphism, which was more prevalent in Hispanic patients, was associated with inferior event-free survival within the Hispanic patient cohort in multivariable modeling, and was a

Effect: decline; HR=3.15

The TCN2 rs1801198 polymorphism, which was more prevalent in Hispanic patients, was associated with inferior event-free survival within the Hispanic patient cohort in multivariable modeling, and was a

Effect: decline; HR=3.15

The TCN2 rs1801198 polymorphism, which was more prevalent in Hispanic patients, was associated with inferior event-free survival within the Hispanic patient cohort in multivariable modeling, and was a

Effect: decline; HR=3.15

The TCN2 rs1801198 polymorphism, which was more prevalent in Hispanic patients, was associated with inferior event-free survival within the Hispanic patient cohort in multivariable modeling, and was a

Effect: decline; HR=3.15

The ABFM regimen in AYA patients caused significant asparaginase-related toxicities including grade 3-4 hepatotoxicity in 41%, pancreatitis in 11%, osteonecrosis in 9%, thrombosis in 19%, and severe a

Effect: adverse; Grade 3-4 liver enzyme elevations in 41%

The ABFM regimen in AYA patients caused significant asparaginase-related toxicities including grade 3-4 hepatotoxicity in 41%, pancreatitis in 11%, osteonecrosis in 9%, thrombosis in 19%, and severe a

Effect: adverse; Grade 3-4 liver enzyme elevations in 41%

The ABFM regimen in AYA patients caused significant asparaginase-related toxicities including grade 3-4 hepatotoxicity in 41%, pancreatitis in 11%, osteonecrosis in 9%, thrombosis in 19%, and severe a

Effect: adverse; Grade 3-4 liver enzyme elevations in 41%

The ABFM regimen in AYA patients caused significant asparaginase-related toxicities including grade 3-4 hepatotoxicity in 41%, pancreatitis in 11%, osteonecrosis in 9%, thrombosis in 19%, and severe a

Effect: adverse; Grade 3-4 liver enzyme elevations in 41%

The ABFM regimen in AYA patients caused significant asparaginase-related toxicities including grade 3-4 hepatotoxicity in 41%, pancreatitis in 11%, osteonecrosis in 9%, thrombosis in 19%, and severe a

Effect: adverse; Grade 3-4 liver enzyme elevations in 41%

The ABFM regimen in AYA patients caused significant asparaginase-related toxicities including grade 3-4 hepatotoxicity in 41%, pancreatitis in 11%, osteonecrosis in 9%, thrombosis in 19%, and severe a

Effect: adverse; Grade 3-4 liver enzyme elevations in 41%

The ABFM regimen in AYA patients caused significant asparaginase-related toxicities including grade 3-4 hepatotoxicity in 41%, pancreatitis in 11%, osteonecrosis in 9%, thrombosis in 19%, and severe a

Effect: adverse; Grade 3-4 liver enzyme elevations in 41%

The ABFM regimen in AYA patients caused significant asparaginase-related toxicities including grade 3-4 hepatotoxicity in 41%, pancreatitis in 11%, osteonecrosis in 9%, thrombosis in 19%, and severe a

Effect: adverse; Grade 3-4 liver enzyme elevations in 41%

The ABFM regimen in AYA patients caused significant asparaginase-related toxicities including grade 3-4 hepatotoxicity in 41%, pancreatitis in 11%, osteonecrosis in 9%, thrombosis in 19%, and severe a

Effect: adverse; Grade 3-4 liver enzyme elevations in 41%

The ABFM regimen in AYA patients caused significant asparaginase-related toxicities including grade 3-4 hepatotoxicity in 41%, pancreatitis in 11%, osteonecrosis in 9%, thrombosis in 19%, and severe a

Effect: adverse; Grade 3-4 liver enzyme elevations in 41%

The ABFM regimen in AYA patients caused significant asparaginase-related toxicities including grade 3-4 hepatotoxicity in 41%, pancreatitis in 11%, osteonecrosis in 9%, thrombosis in 19%, and severe a

Effect: adverse; Grade 3-4 liver enzyme elevations in 41%

The ABFM regimen in AYA patients caused significant asparaginase-related toxicities including grade 3-4 hepatotoxicity in 41%, pancreatitis in 11%, osteonecrosis in 9%, thrombosis in 19%, and severe a

Effect: adverse; Grade 3-4 liver enzyme elevations in 41%

The ABFM regimen in AYA patients caused significant asparaginase-related toxicities including grade 3-4 hepatotoxicity in 41%, pancreatitis in 11%, osteonecrosis in 9%, thrombosis in 19%, and severe a

Effect: adverse; Grade 3-4 liver enzyme elevations in 41%

The ABFM regimen in AYA patients caused significant asparaginase-related toxicities including grade 3-4 hepatotoxicity in 41%, pancreatitis in 11%, osteonecrosis in 9%, thrombosis in 19%, and severe a

Effect: adverse; Grade 3-4 liver enzyme elevations in 41%

The ABFM regimen in AYA patients caused significant asparaginase-related toxicities including grade 3-4 hepatotoxicity in 41%, pancreatitis in 11%, osteonecrosis in 9%, thrombosis in 19%, and severe a

Effect: adverse; Grade 3-4 liver enzyme elevations in 41%

The ABFM regimen in AYA patients caused significant asparaginase-related toxicities including grade 3-4 hepatotoxicity in 41%, pancreatitis in 11%, osteonecrosis in 9%, thrombosis in 19%, and severe a

Effect: adverse; Grade 3-4 liver enzyme elevations in 41%

The ABFM regimen in AYA patients caused significant asparaginase-related toxicities including grade 3-4 hepatotoxicity in 41%, pancreatitis in 11%, osteonecrosis in 9%, thrombosis in 19%, and severe a

Effect: adverse; Grade 3-4 liver enzyme elevations in 41%

The ABFM regimen in AYA patients caused significant asparaginase-related toxicities including grade 3-4 hepatotoxicity in 41%, pancreatitis in 11%, osteonecrosis in 9%, thrombosis in 19%, and severe a

Effect: adverse; Grade 3-4 liver enzyme elevations in 41%

The ABFM regimen in AYA patients caused significant asparaginase-related toxicities including grade 3-4 hepatotoxicity in 41%, pancreatitis in 11%, osteonecrosis in 9%, thrombosis in 19%, and severe a

Effect: adverse; Grade 3-4 liver enzyme elevations in 41%

The ABFM regimen in AYA patients caused significant asparaginase-related toxicities including grade 3-4 hepatotoxicity in 41%, pancreatitis in 11%, osteonecrosis in 9%, thrombosis in 19%, and severe a

Effect: adverse; Grade 3-4 liver enzyme elevations in 41%

The ABFM regimen in AYA patients caused significant asparaginase-related toxicities including grade 3-4 hepatotoxicity in 41%, pancreatitis in 11%, osteonecrosis in 9%, thrombosis in 19%, and severe a

Effect: adverse; Grade 3-4 liver enzyme elevations in 41%

The ABFM regimen in AYA patients caused significant asparaginase-related toxicities including grade 3-4 hepatotoxicity in 41%, pancreatitis in 11%, osteonecrosis in 9%, thrombosis in 19%, and severe a

Effect: adverse; Grade 3-4 liver enzyme elevations in 41%

The ABFM regimen in AYA patients caused significant asparaginase-related toxicities including grade 3-4 hepatotoxicity in 41%, pancreatitis in 11%, osteonecrosis in 9%, thrombosis in 19%, and severe a

Effect: adverse; Grade 3-4 liver enzyme elevations in 41%